The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, will be using these medications. But that estimate may ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

At the end of the day, weight loss options, like any other health-related decisions, are very personal and must be made on a ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia.

weight loss medications are often top of mind. A Google Trends study published in the National Library of Medicine found a significant and growing public interest in GLP-1 agonists between 2023 ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Net Income was $75.6 million, up from a loss of $ ... on the shortage list, and these are compounded versions of Ozempic and Wegovy. Hims & Hers Plans to Bring Generic GLP-1 to Market in 2025 ...